Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

Interleukin-2 (IL-2) is a pluripotent cytokine that regulates the immune system’s response. The IL-2 receptor (IL-2R) is a heterotrimeric protein that binds to IL-2 and reacts to it on the ...

HOUSTON - Coya Therapeutics, Inc. (NASDAQ: COYA), a $109.1 million market cap biotechnology company focusing on regulatory T ...

It is 20 years since the demonstration that immune stimulation of metastatic tumors with interleukin-2 (IL-2) could cause the regression of established human cancers. 1 IL-2 is a lymphocyte ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and ...

HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...